Tags

Type your tag names separated by a space and hit enter

Oral pre-exposure prophylaxis (PrEP) for prevention of HIV in serodiscordant heterosexual couples in the United States: opportunities and challenges.
AIDS Patient Care STDS. 2014 Sep; 28(9):462-74.AP

Abstract

Oral HIV pre-exposure prophylaxis (PrEP) is a promising new biomedical prevention approach in which HIV-negative individuals are provided with daily oral antiretroviral medication for the primary prevention of HIV-1. Several clinical trials have demonstrated efficacy of oral PrEP for HIV prevention among groups at high risk for HIV, with adherence closely associated with level of risk reduction. In the United States (US), three groups have been prioritized for initial implementation of PrEP-injection drug users, men who have sex with men at substantial risk for HIV, and HIV-negative partners within serodiscordant heterosexual couples. Numerous demonstration projects involving PrEP implementation among MSM are underway, but relatively little research has been devoted to study PrEP implementation in HIV-serodiscordant heterosexual couples in the US. Such couples face a unique set of challenges to PrEP implementation at the individual, couple, and provider level with regard to PrEP uptake and maintenance, adherence, safety and toxicity, clinical monitoring, and sexual risk behavior. Oral PrEP also provides new opportunities for serodiscordant couples and healthcare providers for primary prevention and reproductive health. This article provides a review of the critical issues, challenges, and opportunities involved in the implementation of oral PrEP among HIV-serodiscordant heterosexual couples in the US.

Authors+Show Affiliations

1 School of Nursing, University of Rochester Medical Center , Rochester, New York.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural
Review

Language

eng

PubMed ID

25045996

Citation

McMahon, James M., et al. "Oral Pre-exposure Prophylaxis (PrEP) for Prevention of HIV in Serodiscordant Heterosexual Couples in the United States: Opportunities and Challenges." AIDS Patient Care and STDs, vol. 28, no. 9, 2014, pp. 462-74.
McMahon JM, Myers JE, Kurth AE, et al. Oral pre-exposure prophylaxis (PrEP) for prevention of HIV in serodiscordant heterosexual couples in the United States: opportunities and challenges. AIDS Patient Care STDS. 2014;28(9):462-74.
McMahon, J. M., Myers, J. E., Kurth, A. E., Cohen, S. E., Mannheimer, S. B., Simmons, J., Pouget, E. R., Trabold, N., & Haberer, J. E. (2014). Oral pre-exposure prophylaxis (PrEP) for prevention of HIV in serodiscordant heterosexual couples in the United States: opportunities and challenges. AIDS Patient Care and STDs, 28(9), 462-74. https://doi.org/10.1089/apc.2013.0302
McMahon JM, et al. Oral Pre-exposure Prophylaxis (PrEP) for Prevention of HIV in Serodiscordant Heterosexual Couples in the United States: Opportunities and Challenges. AIDS Patient Care STDS. 2014;28(9):462-74. PubMed PMID: 25045996.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Oral pre-exposure prophylaxis (PrEP) for prevention of HIV in serodiscordant heterosexual couples in the United States: opportunities and challenges. AU - McMahon,James M, AU - Myers,Julie E, AU - Kurth,Ann E, AU - Cohen,Stephanie E, AU - Mannheimer,Sharon B, AU - Simmons,Janie, AU - Pouget,Enrique R, AU - Trabold,Nicole, AU - Haberer,Jessica E, Y1 - 2014/07/21/ PY - 2014/7/22/entrez PY - 2014/7/22/pubmed PY - 2014/10/21/medline SP - 462 EP - 74 JF - AIDS patient care and STDs JO - AIDS Patient Care STDS VL - 28 IS - 9 N2 - Oral HIV pre-exposure prophylaxis (PrEP) is a promising new biomedical prevention approach in which HIV-negative individuals are provided with daily oral antiretroviral medication for the primary prevention of HIV-1. Several clinical trials have demonstrated efficacy of oral PrEP for HIV prevention among groups at high risk for HIV, with adherence closely associated with level of risk reduction. In the United States (US), three groups have been prioritized for initial implementation of PrEP-injection drug users, men who have sex with men at substantial risk for HIV, and HIV-negative partners within serodiscordant heterosexual couples. Numerous demonstration projects involving PrEP implementation among MSM are underway, but relatively little research has been devoted to study PrEP implementation in HIV-serodiscordant heterosexual couples in the US. Such couples face a unique set of challenges to PrEP implementation at the individual, couple, and provider level with regard to PrEP uptake and maintenance, adherence, safety and toxicity, clinical monitoring, and sexual risk behavior. Oral PrEP also provides new opportunities for serodiscordant couples and healthcare providers for primary prevention and reproductive health. This article provides a review of the critical issues, challenges, and opportunities involved in the implementation of oral PrEP among HIV-serodiscordant heterosexual couples in the US. SN - 1557-7449 UR - https://www.unboundmedicine.com/medline/citation/25045996/Oral_pre_exposure_prophylaxis__PrEP__for_prevention_of_HIV_in_serodiscordant_heterosexual_couples_in_the_United_States:_opportunities_and_challenges_ L2 - https://www.liebertpub.com/doi/full/10.1089/apc.2013.0302?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -